NUVB
Nuvation Bio Inc.
NYSE · Healthcare · Biotechnology · US
$6.81
+0.59%Year over year
Reported trailing growth
- Revenue
- +1083.6%
- EBITDA
- +36.8%
- EBIT
- +38.7%
- EPS
- +31.0%
- Free cash flow
- +50.9%
- Operating cash flow
- +50.9%
Forward estimates
Based on analyst estimates
- Revenue
- +24.6%
- EBITDA
- +40.4%
- EPS
- +31.0%
Three-year CAGR
- Revenue
- +699.0%
- EBITDA
- +66.6%
- EBIT
- +64.0%
- Net income
- +64.0%
- EPS
- +71.6%
- Free cash flow
- -33.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026